Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 3/2011

01-03-2011 | Review Article

Current status of sentinel lymph-node biopsy in patients with breast cancer

Authors: Gang Cheng, Stephanie Kurita, Drew A. Torigian, Abass Alavi

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 3/2011

Login to get access

Abstract

Axillary node status is the most important prognostic indicator for patients with invasive breast cancer. Sentinel lymph-node biopsy (SLNB) is widely accepted and the preferred procedure for identifying lymph-node metastasis. SLNB allows focused excision and pathological examination of the most likely axillary lymph nodes to receive tumor metastases while avoiding morbidities associated with complete axillary nodal dissection. Since its introduction in the early 1990s, the process of SLNB has undergone continual modification and refinement; however, the procedure varies between institutions and controversies remain. In this review, we examine the technical issues that influence the success of lymph node mapping, discuss the controversies, and summarize the indications and contraindications for axillary node mapping and biopsy in clinical practice.
Literature
1.
Samphao S, Eremin JM, El-Sheemy M, Eremin O. Management of the axilla in women with breast cancer: current clinical practice and a new selective targeted approach. Ann Surg Oncol 2008;15:1282–96.PubMedCrossRef
2.
Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993;2:335–9.PubMedCrossRef
3.
Lyman GH, Giuliano AE, Somerfield MR, Benson 3rd AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:7703–20.PubMedCrossRef
4.
Purushotham AD, Upponi S, Klevesath MB, Bobrow L, Millar K, Myles JP, et al. Morbidity after sentinel lymph node biopsy in primary breast cancer: results from a randomized controlled trial. J Clin Oncol 2005;23:4312–21.PubMedCrossRef
5.
Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon J. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599–609.PubMedCrossRef
6.
McLaughlin SA, Wright MJ, Morris KT, Sampson MR, Brockway JP, Hurley KE, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol 2008;26:5220–6.PubMedCrossRef
7.
McLaughlin SA, Wright MJ, Morris KT, Giron GL, Sampson MR, Brockway JP, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: objective measurements. J Clin Oncol 2008;26:5213–9.PubMedCrossRef
8.
Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 2007;8:881–8.PubMedCrossRef
9.
van der Ploeg IM, Nieweg OE, van Rijk MC, Valdes Olmos RA, Kroon BB. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol 2008;34:1277–84.PubMed
10.
Wilhelm AJ, Mijnhout GS, Franssen EJ. Radiopharmaceuticals in sentinel lymph-node detection – an overview. Eur J Nucl Med 1999;26:S36–42.PubMed
11.
Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001;42:1198–215.PubMed
12.
Leidenius MH, Leppanen EA, Krogerus LA, Smitten KA. The impact of radiopharmaceutical particle size on the visualization and identification of sentinel nodes in breast cancer. Nucl Med Commun 2004;25:233–8.PubMedCrossRef
13.
Glass EC, Essner R, Morton DL. Kinetics of three lymphoscintigraphic agents in patients with cutaneous melanoma. J Nucl Med 1998;39:1185–90.PubMed
14.
Glass EC, Essner R, Giuliano AE. Sentinel node localization in breast cancer. Semin Nucl Med 1999;29:57–68.PubMedCrossRef
15.
Schoder H, Glass EC, Pecking AP, Harness JK, Wallace AM, Hirnle P, et al. Molecular targeting of the lymphovascular system for imaging and therapy. Cancer Metastasis Rev 2006;25:185–201.PubMedCrossRef
16.
Wallace AM, Hoh CK, Darrah DD, Schulteis G, Vera DR. Sentinel lymph node mapping of breast cancer via intradermal administration of Lymphoseek. Nucl Med Biol 2007;34:849–53.PubMedCrossRef
17.
Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer.[see comment]. Ann Surg. 1994;220:391–8.PubMedCrossRef
18.
Masannat Y, Shenoy H, Speirs V, Hanby A, Horgan K. Properties and characteristics of the dyes injected to assist axillary sentinel node localization in breast surgery. Eur J Surg Oncol 2006;32:381–4.PubMedCrossRef
19.
Rodier JF, Velten M, Wilt M, Martel P, Ferron G, Vaini-Elies V, et al. Prospective multicentric randomized study comparing periareolar and peritumoral injection of radiotracer and blue dye for the detection of sentinel lymph node in breast sparing procedures: FRANSENODE trial. J Clin Oncol 2007;25:3664–9.PubMedCrossRef
20.
Noguchi M, Inokuchi M, Zen Y. Complement of peritumoral and subareolar injection in breast cancer sentinel lymph node biopsy. J Surg Oncol 2009;100:100–5.PubMedCrossRef
21.
Kargozaran H, Shah M, Li Y, Beckett L, Gandour-Edwards R, Schneider PD, et al. Concordance of peritumoral technetium 99m colloid and subareolar blue dye injection in breast cancer sentinel lymph node biopsy. J Surg Res 2007;143:126–9.PubMedCrossRef
22.
Varghese P, Abdel-Rahman AT, Akberali S, Mostafa A, Gattuso JM, Carpenter R. Methylene blue dye – a safe and effective alternative for sentinel lymph node localization. Breast J 2008;14:61–7.PubMedCrossRef
23.
Amersi F, Hansen NM. The benefits and limitations of sentinel lymph node biopsy. Curr Treat Options Oncol 2006;7:141–51.PubMedCrossRef
24.
Filippakis GM, Zografos G. Contraindications of sentinel lymph node biopsy: are there any really? World J Surg Oncol 2007;5:10.PubMedCrossRef
25.
Weng PW, Hsu HM, Chen TW, Hsieh CB, Chang TM, Chen VT, et al. Blue angioedema of eyelip after patent blue injection for lymphatic mapping procedure. Eur J Cancer Care 2007;16:390–1.CrossRef
26.
Jaffer U, Badri H, Abdullah TI. Skin necrosis following patent blue V injection for sentinel node detection during breast cancer excision: case report. Breast J 2008;14:508–9.PubMedCrossRef
27.
Bleicher RJ, Kloth DD, Robinson D, Axelrod P. Inflammatory cutaneous adverse effects of methylene blue dye injection for lymphatic mapping/sentinel lymphadenectomy. J Surg Oncol 2009;99:356–60.PubMedCrossRef
28.
Scherer K, Studer W, Figueiredo V, Bircher AJ. Anaphylaxis to isosulfan blue and cross-reactivity to patent blue V: case report and review of the nomenclature of vital blue dyes. Ann Allergy Asthma Immunol 2006;96:497–500.PubMedCrossRef
29.
Chicken DW, Mansouri R, Ell PJ, Keshtgar MR. Allergy to technetium-labelled nanocolloidal albumin for sentinel node identification. Ann R Coll Surg Engl 2007;89:W12–3.PubMedCrossRef
30.
Bauer TW, Spitz FR, Callans LS, Alavi A, Mick R, Weinstein SP, et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 2002;9:169–76.PubMedCrossRef
31.
Pelosi E, Baiocco C, Ala A, Gay E, Bello M, Varetto T, et al. Lymphatic mapping in early stage breast cancer: comparison between periareolar and subdermal injection. Nucl Med Commun 2003;24:519–23.PubMedCrossRef
32.
Derossis AM, Fey J, Yeung H, Yeh SD, Heerdt AS, Petrek J, et al. A trend analysis of the relative value of blue dye and isotope localization in 2,000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001;193:473–8.PubMedCrossRef
33.
Nieweg OE, Estourgie SH, van Rijk MC, Kroon BB. Rationale for superficial injection techniques in lymphatic mapping in breast cancer patients. J Surg Oncol 2004;87:153–6.PubMedCrossRef
34.
Klimberg VS, Rubio IT, Henry R, Cowan C, Colvert M, Korourian S. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999;229:860–4.PubMedCrossRef
35.
Borgstein PJ, Meijer S, Pijpers RJ, van Diest PJ. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000;232:81–9.PubMedCrossRef
36.
Tanis PJ, Nieweg OE, Valdes Olmos RA, Kroon BB. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy. J Am Coll Surg 2001;192:399–409.PubMedCrossRef
37.
Lin KM, Patel TH, Ray A, Ota M, Jacobs L, Kuvshinoff B, et al. Intradermal radioisotope is superior to peritumoral blue dye or radioisotope in identifying breast cancer sentinel nodes. J Am Coll Surg 2004;199:561–6.PubMedCrossRef
38.
Povoski SP, Olsen JO, Young DC, Clarke J, Burak WE, Walker MJ, et al. Prospective randomized clinical trial comparing intradermal, intraparenchymal, and subareolar injection routes for sentinel lymph node mapping and biopsy in breast cancer. Ann Surg Oncol 2006;13:1412–21.PubMedCrossRef
39.
Stojadinovic A, Peoples GE, Jurgens JS, Howard RS, Schuyler B, Kwon KH, et al. Standard versus pH-adjusted and lidocaine supplemented radiocolloid for patients undergoing sentinel-lymph-node mapping and biopsy for early breast cancer (PASSION-P trial): a double-blind, randomised controlled trial. Lancet Oncol 2009;10:849–54.PubMedCrossRef
40.
Argon AM, Duygun U, Acar E, Daglioz G, Yenjay L, Zekioglu O, et al. The use of periareolar intradermal Tc-99m tin colloid and peritumoral intraparenchymal isosulfan blue dye injections for determination of the sentinel lymph node. Clin Nucl Med 2006;31:795–800.PubMedCrossRef
41.
Suami H, Pan WR, Mann GB, Taylor GI. The lymphatic anatomy of the breast and its implications for sentinel lymph node biopsy: a human cadaver study. Ann Surg Oncol 2008;15:863–71.PubMedCrossRef
42.
Tanis PJ, Valdes Olmos RA, Muller SH, Nieweg OE. Lymphatic mapping in patients with breast carcinoma: reproducibility of lymphoscintigraphic results. Radiology 2003;228:546–51.PubMedCrossRef
43.
Gray RJ, Pockaj BA, Roarke MC. Injection of (99m)Tc-labeled sulfur colloid the day before operation for breast cancer sentinel lymph node mapping is as successful as injection the day of operation. Am J Surg 2004;188:685–9.PubMedCrossRef
44.
Babiera GV, Delpassand ES, Breslin TM, Ross MI, Ames FC, Singletary SE, et al. Lymphatic drainage patterns on early versus delayed breast lymphoscintigraphy performed after injection of filtered Tc-99m sulfur colloid in breast cancer patients undergoing sentinel lymph node biopsy. Clin Nucl Med 2005;30:11–5.PubMedCrossRef
45.
Buscombe J, Paganelli G, Burak ZE, Waddington W, Maublant J, Prats E, et al. Sentinel node in breast cancer procedural guidelines. Eur J Nucl Med Mol Imaging 2007;34:2154–9.PubMedCrossRef
46.
Jastrzebski T, Lass P, Swierblewski M, Wydra D, Drucis K, Kruszewski W, et al. The influence of radioisotope vehicle on breast sentinel node detection. Eur J Surg Oncol 2006;32:928–32.PubMedCrossRef
47.
Rousseau C, Classe JM, Campion L, Curtet C, Dravet F, Pioud R, et al. The impact of nonvisualization of sentinel nodes on lymphoscintigraphy in breast cancer. Ann Surg Oncol 2005;12:533–8.PubMedCrossRef
48.
Soran A, Falk J, Bonaventura M, Keenan D, Ahrendt G, Johnson R. Does failure to visualize a sentinel node on preoperative lymphoscintigraphy predict a greater likelihood of axillary lymph node positivity? J Am Coll Surg 2007;205:66–71.PubMedCrossRef
49.
van der Ploeg IMC, Valdes Olmos RA, Kroon BB, Nieweg OE. The hybrid SPECT/CT as an additional lymphatic mapping tool in patients with breast cancer. World J Surg 2008;32:1930–4.PubMedCrossRef
50.
Gil-Rendo A, Zornoza G, Garcia-Velloso MJ, Regueira FM, Beorlegui C, Cervera M. Fluorodeoxyglucose positron emission tomography with sentinel lymph node biopsy for evaluation of axillary involvement in breast cancer. Br J Surg 2006;93:707–12.PubMedCrossRef
51.
Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, et al. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 2008;26:4746–51.PubMedCrossRef
52.
Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 2007;18:473–8.PubMedCrossRef
53.
Kim J, Lee J, Chang E, Kim S, Suh K, Sul J, et al. Selective sentinel node plus additional non-sentinel node biopsy based on an FDG-PET/CT scan in early breast cancer patients: single institutional experience. World J Surg 2009;33:943–9.PubMedCrossRef
54.
Kennedy RJ, Kollias J, Gill PG, Bochner M, Coventry BJ, Farshid G. Removal of two sentinel nodes accurately stages the axilla in breast cancer. Br J Surg 2003;90:1349–53.PubMedCrossRef
55.
Goyal A, Newcombe RG, Mansel RE; Axillary Lymphatic Mapping Against Nodal Axillary Clearance (ALMANAC) Trialists Group. Clinical relevance of multiple sentinel nodes in patients with breast cancer. Br J Surg 2005;92:438–42.PubMedCrossRef
56.
Goyal A, Newcombe RG, Chhabra A, Mansel RE, Group AT. Factors affecting failed localisation and false-negative rates of sentinel node biopsy in breast cancer – results of the ALMANAC validation phase. Breast Cancer Res Treat 2006;99:203–8.PubMedCrossRef
57.
Zakaria S, Degnim AC, Kleer CG, Diehl KA, Cimmino VM, Chang AE, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol 2007;96:554–9.PubMedCrossRef
58.
Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, et al. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer? Cancer 2008;113:30–7.PubMedCrossRef
59.
Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med 1995;36:1775–80.PubMed
60.
Cutler SJ, Axtell LM, Schottenfeld D, Farrow JH. Clinical assessment of lymph nodes in carcinoma of the breast. Surg Gynecol Obstet 1970;131:41–52.PubMed
61.
Specht MC, Fey JV, Borgen PI, Cody HS 3rd. Is the clinically positive axilla in breast cancer really a contraindication to sentinel lymph node biopsy?. J Am Coll Surg 2005;200:10–4.PubMedCrossRef
62.
Lanng C, Hoffmann J, Galatius H, Engel U. Assessment of clinical palpation of the axilla as a criterion for performing the sentinel node procedure in breast cancer. Eur J Surg Oncol 2007;33:281–4.PubMedCrossRef
63.
Kesmodel SB, Canter RJ, Terhune KP, Bauer TW, Mick R, Rosato EF, et al. Use of radiotracer for sentinel lymph node mapping in breast cancer optimizes staging independent of site of administration. Clin Nucl Med 2006;31:527–33.PubMedCrossRef
64.
Anan K, Mitsuyama S, Kuga H, Saimura M, Tanabe Y, Suehara N, et al. Double mapping with subareolar blue dye and peritumoral green dye injections decreases the false-negative rate of dye-only sentinel node biopsy for early breast cancer: 2-site injection is more accurate than 1-site injection. Surgery 2006;139:624–9.PubMedCrossRef
65.
Chagpar A, Martin RC 3rd, Chao C, Wong SL, Edwards MJ, Tuttle T, et al. Validation of subareolar and periareolar injection techniques for breast sentinel lymph node biopsy. Arch Surg 2004;139:614–8.PubMedCrossRef
66.
Motomura K, Komoike Y, Hasegawa Y, Kasugai T, Inaji H, Noguchi S, et al. Intradermal radioisotope injection is superior to subdermal injection for the identification of the sentinel node in breast cancer patients. J Surg Oncol 2003;82:91–6.PubMedCrossRef
67.
D’Eredita G, Ferrarese F, Cecere V, Massa ST, de Carne F, Fabiano G. Subareolar injection may be more accurate than other techniques for sentinel lymph node biopsy in breast cancer. Ann Surg Oncol 2003;10:942–7.PubMedCrossRef
68.
McMasters KM, Wong SL, Martin RC 2nd, Chao C, Tuttle TM, Noyes RD, et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001;233:676–87.PubMedCrossRef
69.
Martin RC, Derossis AM, Fey J, Yeung H, Yeh SD, Akhurst T, et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 2001;130:432–8.PubMedCrossRef
70.
Port ER, Garcia-Etienne CA, Park J, Fey J, Borgen PI, Cody HS 3rd. Reoperative sentinel lymph node biopsy: a new frontier in the management of ipsilateral breast tumor recurrence. Ann Surg Oncol 2007;14:2209–14.PubMedCrossRef
71.
Luini A, Galimberti V, Gatti G, Arnone P, Vento AR, Trifiro G, et al. The sentinel node biopsy after previous breast surgery: preliminary results on 543 patients treated at the European Institute of Oncology. Breast Cancer Res Treat 2005;89:159–63.PubMedCrossRef
72.
Ruano R, Ramos M, Garcia-Talavera JR, Serrano E, De Arriba A, Gonzalez-Orus J, et al. Staging the axilla with selective sentinel node biopsy in patients with previous excision of non-palpable and palpable breast cancer. Eur J Nucl Med Mol Imaging 2008;35:1299–304.PubMedCrossRef
73.
Intra M, Trifiro G, Galimberti V, Gentilini O, Rotmensz N, Veronesi P. Second axillary sentinel node biopsy for ipsilateral breast tumour recurrence. Br J Surg 2007;94:1216–9.PubMedCrossRef
74.
Koizumi M, Koyama M, Tada K, Nishimura S, Miyagi Y, Makita M, et al. The feasibility of sentinel node biopsy in the previously treated breast. Eur J Surg Oncol 2008;34:365–8.PubMed
75.
Gray RJ, Forstner-Barthell AW, Pockaj BA, Schild SE, Halyard MY. Breast-conserving therapy and sentinel lymph node biopsy are feasible in cancer patients with previous implant breast augmentation. Am J Surg 2004;188:122–5.PubMedCrossRef
76.
Rodriguez Fernandez J, Martella S, Trifiro G, Caliskan M, Chifu C, Brenelli F, et al. Sentinel node biopsy in patients with previous breast aesthetic surgery. Ann Surg Oncol 2009;16:989–92.PubMedCrossRef
77.
Karam A, Stempel M, Cody 3rd HS, Port ER. Reoperative sentinel lymph node biopsy after previous mastectomy. J Am Coll Surg 2008;207:543–8.PubMedCrossRef
78.
Port ER, Fey J, Gemignani ML, Heerdt AS, Montgomery LL, Petrek JA, et al. Reoperative sentinel lymph node biopsy: a new option for patients with primary or locally recurrent breast carcinoma. J Am Coll Surg 2002;195:167–72.PubMedCrossRef
79.
Taback B, Nguyen P, Hansen N, Edwards GK, Conway K, Giuliano AE. Sentinel lymph node biopsy for local recurrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006;13:1099–104.PubMedCrossRef
80.
Kumar R, Jana S, Heiba SI, Dakhel M, Axelrod D, Siegel B, et al. Retrospective analysis of sentinel node localization in multifocal, multicentric, palpable, or nonpalpable breast cancer. J Nucl Med 2003;44:7–10.PubMed
81.
Knauer M, Konstantiniuk P, Haid A, Wenzl E, Riegler-Keil M, Postlberger S, et al. Multicentric breast cancer: a new indication for sentinel node biopsy – a multi-institutional validation study. J Clin Oncol 2006;24:3374–80.PubMedCrossRef
82.
Hsueh EC, Turner RR, Glass EC, Brenner RJ, Brennan MB, Giuliano AE. Sentinel node biopsy in breast cancer. J Am Coll Surg 1999;189:207–13.PubMedCrossRef
83.
Goyal A, Newcombe RG, Mansel RE, Chetty U, Ell P, Fallowfield L, et al. Sentinel lymph node biopsy in patients with multifocal breast cancer. Eur J Surg Oncol 2004;30:475–9.PubMedCrossRef
84.
D’Eredita G, Giardina C, Ingravallo G, Rubini G, Lattanzio V, Berardi T. Sentinel lymph node biopsy in multiple breast cancer using subareolar injection of the tracer. Breast 2007;16:316–22.PubMedCrossRef
85.
Krynyckyi BR, Chun H, Kim HH, Eskandar Y, Kim CK, Machac J. Factors affecting visualization rates of internal mammary sentinel nodes during lymphoscintigraphy. J Nucl Med 2003;44:1387–93.PubMed
86.
Paredes P, Vidal-Sicart S, Zanon G, Pahisa J, Fernandez PL, Velasco M, et al. Clinical relevance of sentinel lymph nodes in the internal mammary chain in breast cancer patients. Eur J Nucl Med Mol Imaging 2005;32:1283–7.PubMedCrossRef
87.
Climaco F, Coelho-Oliveira A, Djahjah MC, Gutfilen B, Correia AH, Noe R, et al. Sentinel lymph node identification in breast cancer: a comparison study of deep versus superficial injection of radiopharmaceutical. Nucl Med Commun 2009;30:525–32.PubMedCrossRef
88.
van der Ent FW, Kengen RA, van der Pol HA, Povel JA, Stroeken HJ, Hoofwijk AG. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001;234:79–84.PubMedCrossRef
89.
Bourre JC, Payan R, Collomb D, Gallazzini-Crepin C, Calizzano A, Desruet MD, et al. Can the sentinel lymph node technique affect decisions to offer internal mammary chain irradiation? Eur J Nucl Med Mol Imaging 2009;36:758–64.PubMedCrossRef
90.
Estourgie SH, Tanis PJ, Nieweg OE, Valdes Olmos RA, Rutgers EJ, Kroon BB. Should the hunt for internal mammary chain sentinel nodes begin? An evaluation of 150 breast cancer patients. Ann Surg Oncol 2003;10:935–41.PubMedCrossRef
91.
Veronesi U, Marubini E, Mariani L, Valagussa P, Zucali R. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. Eur J Cancer 1999;35:1320–5.PubMedCrossRef
92.
Dowlatshahi K, Fan M, Anderson JM, Bloom KJ. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 2001;8:675–81.PubMedCrossRef
93.
Patani N, Mokbel K. The clinical significance of sentinel lymph node micrometastasis in breast cancer. Breast Cancer Res Treat 2009;114:393–402.PubMedCrossRef
94.
van Rijk MC, Peterse JL, Nieweg OE, Oldenburg HS, Rutgers EJ, Kroon BB. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 2006;107:467–71.PubMedCrossRef
95.
Cox CE, Kiluk JV, Riker AI, Cox JM, Allred N, Ramos DC, et al. Significance of sentinel lymph node micrometastases in human breast cancer. J Am Coll Surg 2008;206:261–8.PubMedCrossRef
96.
Carcoforo P, Bergossi L, Basaglia E, Soliani G, Querzoli P, Zambrini E, et al. Prognostic and therapeutic impact of sentinel node micrometastasis in patients with invasive breast cancer. Tumori 2002;88:S4–5.PubMed
97.
Bulte CS, van der Heiden-van der Loo M, Hennipman A. Axillary recurrence rate after tumour negative and micrometastatic positive sentinel node procedures in breast cancer patients, a population based multicenter study. Eur J Surg Oncol 2009;35:25–31.PubMed
98.
Gobardhan PD, Elias SG, Madsen EV, Bongers V, Ruitenberg HJ, Perre CI, et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 2009;20:41–8.PubMedCrossRef
99.
Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol 2009;27:2946–53.PubMedCrossRef
100.
Sakr R, Bezu C, Raoust I, Antoine M, Ettore F, Darcourt J, et al. The sentinel lymph node procedure for patients with preoperative diagnosis of ductal carcinoma in situ: risk factors for unsuspected invasive disease and for metastatic sentinel lymph nodes. Int J Clin Pract 2008;62:1730–5.PubMedCrossRef
101.
Sakr R, Antoine M, Barranger E, Dubernard G, Salem C, Darai E, et al. Value of sentinel lymph node biopsy in breast ductal carcinoma in situ upstaged to invasive carcinoma. Breast J 2008;14:55–60.PubMedCrossRef
102.
Intra M, Rotmensz N, Veronesi P, Colleoni M, Iodice S, Paganelli G, et al. Sentinel node biopsy is not a standard procedure in ductal carcinoma in situ of the breast: the experience of the European Institute of Oncology on 854 patients in 10 years. Ann Surg 2008;247:315–9.PubMedCrossRef
103.
Dominguez FJ, Golshan M, Black DM, Hughes KS, Gadd MA, Christian R, et al. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ. Ann Surg Oncol 2008;15:268–73.PubMedCrossRef
104.
Ansari B, Ogston SA, Purdie CA, Adamson DJ, Brown DC, Thompson AM. Meta-analysis of sentinel node biopsy in ductal carcinoma in situ of the breast. Br J Surg 2008;95:547–54.PubMedCrossRef
105.
Mondi MM, Cuenca RE, Ollila DW, Stewart JH 4th, Levine EA. Sentinel lymph node biopsy during pregnancy: initial clinical experience. Ann Surg Oncol 2007;14:218–21.PubMedCrossRef
106.
Khera SY, Kiluk JV, Hasson DM, Meade TL, Meyers MP, Dupont EL, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J 2008;14:250–4.PubMedCrossRef
107.
Gentilini O, Cremonesi M, Trifiro G, Ferrari M, Baio SM, Caracciolo M, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol 2004;15:1348–51.PubMedCrossRef
108.
Pandit-Taskar N, Dauer LT, Montgomery L, St Germain J, Zanzonico PB, Divgi CR. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients. J Nucl Med 2006;47:1202–8.PubMed
109.
Spanheimer PM, Graham MM, Sugg SL, Scott-Conner CEH, Weigel RJ. Measurement of uterine radiation exposure from lymphoscintigraphy indicates safety of sentinel lymph node biopsy during pregnancy. Ann Surg Oncol 2009;16:1143–7.PubMedCrossRef
110.
Boughey JC, Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer HM, Akins JS, et al. Comparative analysis of sentinel lymph node operation in male and female breast cancer patients. J Am Coll Surg 2006;203:475–80.PubMedCrossRef
111.
Gentilini O, Chagas E, Zurrida S, Intra M, De Cicco C, Gatti G, et al. Sentinel lymph node biopsy in male patients with early breast cancer. Oncologist 2007;12:512–5.PubMedCrossRef
112.
Flynn LW, Park J, Patil SM, Cody HS 3rd, Port ER. Sentinel lymph node biopsy is successful and accurate in male breast carcinoma. J Am Coll Surg 2008;206:616–21.PubMed
113.
Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694–702.PubMedCrossRef
114.
Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol 2009;27:726–32.PubMedCrossRef
115.
Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy – systematic review and meta analysis. Acad Radiol 2009;16:551–63.PubMedCrossRef
116.
Heuts EM, van der Ent FW, van der Pol HA, von Meyenfeldt MF, Voogd AC. Additional tracer injection to improve the technical success rate of lymphoscintigraphy for sentinel node biopsy in breast cancer. Ann Surg Oncol 2009;16:1156–63.PubMedCrossRef
117.
van der Ploeg IM, Olmos RA, Kroon BB, Rutgers EJ, Nieweg OE. The hidden sentinel node and SPECT/CT in breast cancer patients. Eur J Nucl Med Mol Imaging 2009;36:6–11.PubMedCrossRef
118.
Brenot-Rossi I, Houvenaeghel G, Jacquemier J, Bardou VJ, Martino M, Hassan-Sebbag N, et al. Nonvisualization of axillary sentinel node during lymphoscintigraphy: is there a pathologic significance in breast cancer? J Nucl Med 2003;44:1232–7.PubMed
119.
Lo YF, Hsueh S, Ma SY, Chen SC, Chen MF. Clinical relevance of nonvisualized sentinel lymph nodes in unselected breast cancer patients during lymphoscintigraphy. Chang Gung Med J 2005;28:378–86.PubMed
120.
Kim T, Giuliano AE, Lyman GH. Lymphatic mapping and sentinel lymph node biopsy in early-stage breast carcinoma: a metaanalysis. Cancer 2006;106:4–16.PubMedCrossRef
121.
Schirrmeister H, Kotzerke J, Vogl F, Buck A, Czech N, Koretz K, et al. Prospective evaluation of factors influencing success rates of sentinel node biopsy in 814 breast cancer patients. Cancer Biother Radiopharm 2004;19:784–90.PubMedCrossRef
122.
Horvath JW, Barnett GE, Jimenez RE, Young DC, Povoski SP. Comparison of intraoperative frozen section analysis for sentinel lymph node biopsy during breast cancer surgery for invasive lobular carcinoma and invasive ductal carcinoma. World J Surg Oncol 2009;7:34.PubMedCrossRef
123.
van de Vrande S, Meijer J, Rijnders A, Klinkenbijl JH. The value of intraoperative frozen section examination of sentinel lymph nodes in breast cancer. Eur J Surg Oncol 2009;35:276–80.PubMed
124.
Tille J-C, Egger J-F, Devillaz MC, Vlastos G, Pelte M-F. Frozen section in axillary sentinel lymph nodes for diagnosis of breast cancer micrometastasis. Anticancer Res 2009;29:4711–6.PubMed
125.
Takei H, Kurosumi M, Yoshida T, Ishikawa Y, Hayashi Y, Ninomiya J, et al. Axillary lymph node dissection can be avoided in women with breast cancer with intraoperative, false-negative sentinel lymph node biopsies. Breast Cancer 2010;17:9–16.PubMedCrossRef
126.
Jensen AJ, Naik AM, Pommier RF, Vetto JT, Troxell ML. Factors influencing accuracy of axillary sentinel lymph node frozen section for breast cancer. Am J Surg 2010;199:629–35.PubMedCrossRef
127.
Olson JA Jr, McCall LM, Beitsch P, Whitworth PW, Reintgen DS, Blumencranz PW, et al. Impact of immediate versus delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes: results from American College of Surgeons Oncology Group Trials Z0010 and Z0011. J Clin Oncol 2008;26:3530–5.PubMedCrossRef
128.
Langer I, Marti WR, Guller U, Moch H, Harder F, Oertli D, et al. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005;241:152–8.PubMed
129.
Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer 2007;110:723–30.PubMedCrossRef
130.
Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody 3rd HS. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg 2007;245:462–8.PubMedCrossRef
131.
Zakaria S, Pantvaidya G, Reynolds CA, Grant CS, Sterioff S, Donohue JH, et al. Sentinel node positive breast cancer patients who do not undergo axillary dissection: are they different? Surgery 2008;143:641–7.PubMedCrossRef
132.
Taras AR, Hendrickson NA, Lowe KA, Atwood M, Beatty JD. Recurrence rates in breast cancer patients with false-negative intraoperative evaluation of sentinel lymph nodes. Am J Surg 2010;199:625–8.PubMedCrossRef
Metadata
Title
Current status of sentinel lymph-node biopsy in patients with breast cancer
Authors
Gang Cheng
Stephanie Kurita
Drew A. Torigian
Abass Alavi
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 3/2011
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-010-1577-z

Other articles of this Issue 3/2011

European Journal of Nuclear Medicine and Molecular Imaging 3/2011 Go to the issue

Book Review

Orrison WW Jr: Atlas of Brain Function, 2nd edn.

Short Communication

Pathophysiologic correlates of 82Rb biodistribution in cardiac PET/CT

Short Communication

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

Original Article

Long-term smoking causes more advanced coronary endothelial dysfunction in middle-aged smokers compared to young smokers

Image of the Month

18F-FDG PET/CT for the diagnosis of sarcoidosis in a patient with bilateral inflammatory involvement of the parotid and lacrimal glands (panda sign) and bilateral hilar and mediastinal lymphadenopathy (lambda sign)

Original Article

Diagnostic 131I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up